The industrial power sector is at a tipping point in 2026, where decades-old RS-232 communication standards are finally yielding to the demands of modern, Ethernet-based substation automation. Rather ...

ABB will provide leading process control, electrification and drives solutions at the new Novada Cement Plant in Florida.

A small, unknown band of hackers pulled off history's first recorded, truly artificial intelligence-directed cyberattack ...

In this post, we will show you how to create email templates in the new Outlook app for Windows 11. Creating email or message templates in Microsoft Outlook (classic) involved manually composing an ...

As artificial intelligence (AI) training reshapes data center power system design, early adopters using battery energy ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

The International Society of Automation (ISA) has published a new standard: ANSI/ISA-112.00.01-2025, SCADA Systems – Part 1: SCADA Lifecycle, Diagrams and Terminology. According to ISA, this standard ...

As seen on diginomica passim, the music industry has a complicated relationship with data and AI. While there’s justifiable concern that emerging technology can be used to shortcut the creative ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...